Expert Interview
A Second View: Discussing Pluvicto for the treatment of metastatic or castrate-resistant prostate cancer in light of its recent FDA approval.
Ticker(s): NVSInstitution: Precision Radiotherapy
- Radiation Oncologist at Precision Radiotherapy
- Manages between 50 patients with metastatic or castrate-resistant prostate cancer on a monthly basis
- Familiar with the phase 3 data for the Pluvicto trial
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
